Sentinel lymph node biopsy in the management of conjunctival melanoma: current insights

Joel M Mor,1 Alexander C Rokohl,1 Konrad R Koch,1 Ludwig M Heindl1,21Department of Ophthalmology, University of Cologne, Cologne, Germany; 2Center for Integrated Oncology (CIO) Aachen-Bonn-Cologne-Duesseldorf, Ophthalmic Oncology Unit, Cologne, GermanyPurpose: To evaluate the role of sentinel lymph...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mor JM, Rokohl AC, Koch KR, Heindl LM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	Sentinel – Biopsy – Conjunctival Melanoma – Lymphatic spread – Lymph node Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/75cff8bf975042c5aa83800a5d8d46e6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:75cff8bf975042c5aa83800a5d8d46e6
record_format	dspace
spelling	oai:doaj.org-article:75cff8bf975042c5aa83800a5d8d46e62021-12-02T05:43:59ZSentinel lymph node biopsy in the management of conjunctival melanoma: current insights1177-5483https://doaj.org/article/75cff8bf975042c5aa83800a5d8d46e62019-07-01T00:00:00Zhttps://www.dovepress.com/sentinel-lymph-node-biopsy-in-the-management-of-conjunctival-melanoma--peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Joel M Mor,1 Alexander C Rokohl,1 Konrad R Koch,1 Ludwig M Heindl1,21Department of Ophthalmology, University of Cologne, Cologne, Germany; 2Center for Integrated Oncology (CIO) Aachen-Bonn-Cologne-Duesseldorf, Ophthalmic Oncology Unit, Cologne, GermanyPurpose: To evaluate the role of sentinel lymph node biopsy (SLNB) in conjunctival melanoma (CM).Methods: This article provides a review of the literature from PUBMED.Results: Data on SLNB in the management of CM are scarce and only two relatively large cohorts have been reported. Although indication criteria for SLNB vary slightly, positive findings can be expected in 11%–13% of CM cases, including small tumors. False negative SLNB findings are rare (<10%). Failure to identify SLNB has been attributed to the surgical learning curve and recurrent tumors with scar tissue impeding spread of the tracer material. Reported 5-year survival rate following CM management including SLNB, is up to 79%, but there are no comparative cohort studies proving the assumed benefit. Adverse events reported were non-severe and transient.Conclusion: Patients can potentially benefit from SLNB and the procedure can be offered to eligible patients. However, there is not enough evidence to support SLNB as a mandatory part of CM management.Keywords: sentinel, biopsy, conjunctival melanoma, lymphatic spread, lymph nodeMor JMRokohl ACKoch KRHeindl LMDove Medical PressarticleSentinel – Biopsy – Conjunctival Melanoma – Lymphatic spread – Lymph nodeOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 13, Pp 1297-1302 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Sentinel – Biopsy – Conjunctival Melanoma – Lymphatic spread – Lymph node Ophthalmology RE1-994
spellingShingle	Sentinel – Biopsy – Conjunctival Melanoma – Lymphatic spread – Lymph node Ophthalmology RE1-994 Mor JM Rokohl AC Koch KR Heindl LM Sentinel lymph node biopsy in the management of conjunctival melanoma: current insights
description	Joel M Mor,1 Alexander C Rokohl,1 Konrad R Koch,1 Ludwig M Heindl1,21Department of Ophthalmology, University of Cologne, Cologne, Germany; 2Center for Integrated Oncology (CIO) Aachen-Bonn-Cologne-Duesseldorf, Ophthalmic Oncology Unit, Cologne, GermanyPurpose: To evaluate the role of sentinel lymph node biopsy (SLNB) in conjunctival melanoma (CM).Methods: This article provides a review of the literature from PUBMED.Results: Data on SLNB in the management of CM are scarce and only two relatively large cohorts have been reported. Although indication criteria for SLNB vary slightly, positive findings can be expected in 11%–13% of CM cases, including small tumors. False negative SLNB findings are rare (<10%). Failure to identify SLNB has been attributed to the surgical learning curve and recurrent tumors with scar tissue impeding spread of the tracer material. Reported 5-year survival rate following CM management including SLNB, is up to 79%, but there are no comparative cohort studies proving the assumed benefit. Adverse events reported were non-severe and transient.Conclusion: Patients can potentially benefit from SLNB and the procedure can be offered to eligible patients. However, there is not enough evidence to support SLNB as a mandatory part of CM management.Keywords: sentinel, biopsy, conjunctival melanoma, lymphatic spread, lymph node
format	article
author	Mor JM Rokohl AC Koch KR Heindl LM
author_facet	Mor JM Rokohl AC Koch KR Heindl LM
author_sort	Mor JM
title	Sentinel lymph node biopsy in the management of conjunctival melanoma: current insights
title_short	Sentinel lymph node biopsy in the management of conjunctival melanoma: current insights
title_full	Sentinel lymph node biopsy in the management of conjunctival melanoma: current insights
title_fullStr	Sentinel lymph node biopsy in the management of conjunctival melanoma: current insights
title_full_unstemmed	Sentinel lymph node biopsy in the management of conjunctival melanoma: current insights
title_sort	sentinel lymph node biopsy in the management of conjunctival melanoma: current insights
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/75cff8bf975042c5aa83800a5d8d46e6
work_keys_str_mv	AT morjm sentinellymphnodebiopsyinthemanagementofconjunctivalmelanomacurrentinsights AT rokohlac sentinellymphnodebiopsyinthemanagementofconjunctivalmelanomacurrentinsights AT kochkr sentinellymphnodebiopsyinthemanagementofconjunctivalmelanomacurrentinsights AT heindllm sentinellymphnodebiopsyinthemanagementofconjunctivalmelanomacurrentinsights
_version_	1718400237109772288

Sentinel lymph node biopsy in the management of conjunctival melanoma: current insights

Ejemplares similares